Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial

Summary Aims: We aimed to compare the effect of risedronate (RIS) and teriparatide (TPTD) (recombinant human parathyroid hormone 1–34) on bone turnover markers in women with postmenopausal osteoporosis. Methods: Forty‐four Caucasian women (age 65.1 ± 1.6 years) with postmenopausal osteoporosis were randomly assigned to receive either RIS 35 mg once weekly (n = 22) or TPTD 20 μg once daily (n = 22) for 12 months. Serum N‐terminal propeptide of type 1 collagen (P1NP), C‐terminal telopeptide of type 1 collagen (CTx), total alkaline phosphatase (ALP) and intact parathyroid hormone (iPTH) were obtained from all women before, 3 and 6 months after treatment initiation. Lumbar spine bone mineral density (BMD) was measured by dual‐energy X‐ray absorptiometry before and 12 months after treatment initiation. Results: P1NP, CTx and total ALP levels decreased in RIS group (p